Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Asset Writedowns and Impairment (2018 - 2025)

Historic Asset Writedowns and Impairment for Bio-Techne (TECH) over the last 5 years, with Q2 2025 value amounting to $84.2 million.

  • Bio-Techne's Asset Writedowns and Impairment rose 42846.47% to $84.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $96.4 million, marking a year-over-year increase of 50551.33%. This contributed to the annual value of $80.5 million for FY2025, which is 26653.92% up from last year.
  • Latest data reveals that Bio-Techne reported Asset Writedowns and Impairment of $84.2 million as of Q2 2025, which was up 42846.47% from -$3.7 million recorded in Q1 2025.
  • In the past 5 years, Bio-Techne's Asset Writedowns and Impairment ranged from a high of $84.2 million in Q2 2025 and a low of -$3.7 million during Q1 2025
  • Its 3-year average for Asset Writedowns and Impairment is $23.0 million, with a median of $15.9 million in 2024.
  • Examining YoY changes over the last 5 years, Bio-Techne's Asset Writedowns and Impairment showed a top increase of 42846.47% in 2025 and a maximum decrease of 42846.47% in 2025.
  • Quarter analysis of 3 years shows Bio-Techne's Asset Writedowns and Impairment stood at $18.2 million in 2021, then fell by 12.35% to $15.9 million in 2024, then soared by 428.46% to $84.2 million in 2025.
  • Its last three reported values are $84.2 million in Q2 2025, -$3.7 million for Q1 2025, and $15.9 million during Q2 2024.